Condition
HLA-A2 Positive Cells Present
Total Trials
3
Recruiting
0
Active
0
Completed
1
Success Rate
33.3%-53% vs avg
Key Insights
Highlights
Success Rate
33% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 75/100
Termination Rate
66.7%
2 terminated out of 3 trials
Success Rate
33.3%
-53.2% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
300%
3 of 1 completed with results
Key Signals
3 with results33% success
Data Visualizations
Phase Distribution
3Total
Early P 1 (1)
P 1 (1)
P 2 (1)
Trial Status
Terminated2
Completed1
Trial Success Rate
33.3%
Benchmark: 86.5%
Based on 1 completed trials
Clinical Trials (3)
Showing 3 of 3 trials
NCT04093323Phase 2TerminatedPrimary
Polarized Dendritic Cell (aDC1) Based Treatment, Interferon Alpha-2, Rintatolimod, and Celecoxib for the Treatment of HLA-A2+ Refractory Melanoma
NCT00194714Phase 1Completed
Vaccine Therapy in Treating Patients With Stage IV HLA-A2 and HER2 Positive Breast or Ovarian Cancer Receiving Trastuzumab
NCT02774291Early Phase 1TerminatedPrimary
Anti-NY ESO-1 mTCR Peripheral Blood Lymphocytes
Showing all 3 trials